» Authors » Siobhan I Davis

Siobhan I Davis

Explore the profile of Siobhan I Davis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 1407
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis S, Biswas J, White S
BMJ Mil Health . 2020 Dec; 166(6):411-413. PMID: 33293376
Disease non-battle injury has plagued British expeditionary forces through the ages. While in recent years significant mortality has reduced, it has had a large impact on operational effectiveness, at times...
2.
Farrow E, Yu X, Summers L, Davis S, Fleet J, Allen M, et al.
Proc Natl Acad Sci U S A . 2011 Oct; 108(46):E1146-55. PMID: 22006328
Autosomal dominant hypophosphatemic rickets (ADHR) is unique among the disorders involving Fibroblast growth factor 23 (FGF23) because individuals with R176Q/W and R179Q/W mutations in the FGF23 (176)RXXR(179)/S(180) proteolytic cleavage motif...
3.
Farrow E, Davis S, Summers L, White K
J Am Soc Nephrol . 2009 Apr; 20(5):955-60. PMID: 19357251
Fibroblast growth factor-23 (FGF23), a hormone central to phosphate and vitamin D metabolism, reduces renal absorption of phosphate by downregulating the sodium-phosphate cotransporter Npt2a. However, the mechanisms of FGF23 action...
4.
Farrow E, Davis S, Ward L, Summers L, Bubbear J, Keen R, et al.
Bone . 2008 Nov; 44(2):287-94. PMID: 19007919
We previously demonstrated that the mutations Met1Val (M1V) and the deletion of nucleotides 1484-1490 (1484-1490del) in Dentin matrix protein-1 (DMP1) cause the novel disorder autosomal recessive hypophosphatemic rickets (ARHR), which...
5.
Garringer H, Malekpour M, Esteghamat F, Mortazavi S, Davis S, Farrow E, et al.
Am J Physiol Endocrinol Metab . 2008 Aug; 295(4):E929-37. PMID: 18682534
Fibroblast growth factor 23 (FGF23) is a hormone required for normal renal phosphate reabsorption. FGF23 gain-of-function mutations result in autosomal dominant hypophosphatemic rickets (ADHR), and FGF23 loss-of-function mutations cause familial...
6.
Garringer H, Mortazavi S, Esteghamat F, Malekpour M, Boztepe H, Tanakol R, et al.
Am J Med Genet A . 2007 Sep; 143A(20):2390-6. PMID: 17853462
Familial tumoral calcinosis (TC) is characterized by elevated serum phosphate concentrations, normal or elevated 1,25(OH)2 vitamin D, as well as periarticular and vascular calcifications. Recessive mutations in the mucin-like glycosyltransferase...
7.
Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B, et al.
Nat Genet . 2006 Oct; 38(11):1310-5. PMID: 17033621
The osteocyte, a terminally differentiated cell comprising 90%-95% of all bone cells, may have multiple functions, including acting as a mechanosensor in bone (re)modeling. Dentin matrix protein 1 (encoded by...
8.
Garringer H, Fisher C, Larsson T, Davis S, Koller D, Cullen M, et al.
J Clin Endocrinol Metab . 2006 Jul; 91(10):4037-42. PMID: 16868048
Context: Familial tumoral calcinosis (TC) results from disruptions in phosphate metabolism and is characterized by high serum phosphate with normal or elevated 1,25 dihydroxyvitamin vitamin D concentrations and ectopic and...
9.
Farrow E, Davis S, Mooney S, Beighton P, Mascarenhas L, Gutierrez Y, et al.
Am J Med Genet A . 2006 Feb; 140(5):537-9. PMID: 16470795
No abstract available.
10.
Yu X, Ibrahimi O, Goetz R, Zhang F, Davis S, Garringer H, et al.
Endocrinology . 2005 Aug; 146(11):4647-56. PMID: 16081635
Fibroblast growth factor (FGF)-23 has emerged as an endocrine regulator of phosphate and of vitamin D metabolism. It is produced in bone and, unlike other FGFs, circulates in the bloodstream...